Literature DB >> 24390145

Output correlations in probabilistic models with multiple alternatives.

Klemen Naveršnik1.   

Abstract

A comprehensive cost-effectiveness decision model will often go beyond a one-to-one comparison and will include a number of competing alternatives. Only a simultaneous assessment of all relevant treatment alternatives avoids comparing average cost-effectiveness ratios and allows a truly incremental analysis. Two issues arise if the analysis is probabilistic, namely, the occurrence of output correlations and difficulty in presenting the results. I have examined the role of output correlations using a screening model with eight alternatives and have shown that specifically cost-cost and quality-adjusted life years (QALY)-QALY correlations between alternatives have a major impact on decision uncertainty, as measured by the probability of the cost-effectiveness and expected value of perfect information. In particular, the latter strongly depends on between-alternative output correlations. This analysis shows that both the expected value of perfect information plots and acceptability curves/frontiers are sensitive to output correlations and thus appropriate for presentation of multiple alternatives. To avoid confusing statistical significance and economic importance I propose that acceptability curves be augmented by incremental net-benefit density plots at a given willingness to pay threshold.

Mesh:

Year:  2014        PMID: 24390145     DOI: 10.1007/s10198-013-0558-0

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  20 in total

1.  Cost-effectiveness analysis with risk aversion.

Authors:  J G Zivin
Journal:  Health Econ       Date:  2001-09       Impact factor: 3.046

2.  Communicating uncertainty in economic evaluations: verifying optimal strategies.

Authors:  H Koffijberg; G A de Wit; T L Feenstra
Journal:  Med Decis Making       Date:  2012-02-28       Impact factor: 2.583

3.  Cost-effectiveness acceptability curves in the dock: case not proven?

Authors:  Elisabeth Fenwick; Andrew Briggs
Journal:  Med Decis Making       Date:  2007 Mar-Apr       Impact factor: 2.583

4.  Presenting results of probabilistic sensitivity analysis: the incremental benefit curve.

Authors:  Mohan V Bala; Gary A Zarkin; Josephine Mauskopf
Journal:  Health Econ       Date:  2008-03       Impact factor: 3.046

5.  Handling input correlations in pharmacoeconomic models.

Authors:  Klemen Naveršnik; Klemen Rojnik
Journal:  Value Health       Date:  2012-02-17       Impact factor: 5.725

6.  Sample size and power for cost-effectiveness analysis (part 1).

Authors:  Henry A Glick
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

7.  Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.

Authors:  Bas Groot Koerkamp; M G Myriam Hunink; Theo Stijnen; James K Hammitt; Karen M Kuntz; Milton C Weinstein
Journal:  Med Decis Making       Date:  2007 Mar-Apr       Impact factor: 2.583

8.  Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).

Authors:  Garry R Barton; Andrew H Briggs; Elisabeth A L Fenwick
Journal:  Value Health       Date:  2008-05-16       Impact factor: 5.725

9.  Cost-effectiveness acceptability curves--caveats quantified.

Authors:  Michał Jakubczyk; Bogumił Kamiński
Journal:  Health Econ       Date:  2010-08       Impact factor: 3.046

10.  Deriving input parameters for cost-effectiveness modeling: taxonomy of data types and approaches to their statistical synthesis.

Authors:  Pedro Saramago; Andrea Manca; Alex J Sutton
Journal:  Value Health       Date:  2012-05-23       Impact factor: 5.725

View more
  1 in total

1.  Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.

Authors:  Henri B Wolff; Venetia Qendri; Natalia Kunst; Fernando Alarid-Escudero; Veerle M H Coupé
Journal:  Med Decis Making       Date:  2022-05-19       Impact factor: 2.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.